Prevalence & Suggested Testing for KRAS G12C Mutation in NSCLC
​

 

 

FIND KRAS G12C

13% (1 in 8) of patients with non-squamous NSCLC have the KRAS G12C mutation, yet too many of these patients go unidentified.

Consider testing for all actionable mutations in eligible patients with NSCLC at diagnosis and help Find KRAS G12C.

​

KRAS G12C mutationKRAS G12C mutation

KRAS G12C mutation

Investigating KRAS G12C inhibitionInvestigating KRAS G12C inhibition

Investigating KRASG12C inhibition

CTA_educational_resourcesCTA_educational_resources

KRAS G12C
educational resources

KRAS, Kirsten rat sarcoma; NSCLC, non-small cell lung cancer.

Reference: Data on file, Amgen; [Analysis of AACR Genie v8].